Metabolic dysfunction-associated steatotic liver disease after pancreaticoduodenectomy: Mechanisms, clinical impact, and therapeutic implications.
文献摘要
Pancreaticoduodenectomy (PD) is associated with increasingly recognized long-term metabolic sequelae. Among these, metabolic dysfunction-associated steatotic liver disease (MASLD) is emerging as a frequent but underappreciated phenomenon. Current evidence suggests that post-PD MASLD may represent a distinct metabolic phenotype driven predominantly by pancreatic exocrine and endocrine insufficiency, malnutrition, and altered gastrointestinal physiology rather than classical metabolic syndrome. These alterations may disrupt lipid metabolism, mitochondrial function, and hepatocellular homeostasis, promoting hepatic steatosis. Limited observational evidence has also associated post-PD MASLD with poorer survival, reduced chemotherapy tolerance, and challenges in postoperative imaging surveillance. Further characterization of its pathophysiology and clinical significance is needed to inform preventive and treatment strategies and optimize long-term outcomes. This review aims to summarize current evidence on the incidence, pathophysiology, clinical significance, and management of de novo MASLD following PD.